Functional impact of exercise pulmonary hypertension in patients with borderline resting pulmonary arterial pressure

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation       | Oliveira, Rudolf K. F., Mariana Faria-Urbina, Bradley A. Maron, Mario Santos, Aaron B. Waxman, and David M. Systrom. 2017. “Functional impact of exercise pulmonary hypertension in patients with borderline resting pulmonary arterial pressure.” Pulmonary Circulation 7 (3): 654-665. doi:10.1177/2045893217709025. http://dx.doi.org/10.1177/2045893217709025. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Published Version | doi:10.1177/2045893217709025                                                                                                                                                                                                                                                                                                                                                       |
| Citable link    | http://nrs.harvard.edu/urn-3:HUL.InstRepos:35981927                                                                                                                                                                                                                                                                                                                               |
| Terms of Use    | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA                                                                                                                                               |
Functional impact of exercise pulmonary hypertension in patients with borderline resting pulmonary arterial pressure

Rudolf K. F. Oliveira1,2,3, Mariana Faria-Urbina1,2, Bradley A. Maron4,5, Mario Santos6, Aaron B. Waxman1,2 and David M. Systrom1,2

1Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA; 2Heart & Vascular Center, Brigham and Women’s Hospital, Boston, MA, USA; 3Division of Respiratory Diseases, Department of Medicine, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil; 4Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA; 5Veterans Affairs Boston Healthcare System, Boston, MA, USA; 6Department of Physiology and Cardiothoracic Surgery, Cardiovascular R&D Unit, Faculty of Medicine, University of Porto, Portugal

Abstract
Borderline resting mean pulmonary arterial pressure (mPAP) is associated with adverse outcomes and affects the exercise pulmonary vascular response. However, the pathophysiological mechanisms underlying exertional intolerance in borderline mPAP remain incompletely characterized. In the current study, we sought to evaluate the prevalence and functional impact of exercise pulmonary hypertension (ePH) across a spectrum of resting mPAP’s in consecutive patients with contemporary resting right heart catheterization (RHC) and invasive cardiopulmonary exercise testing. Patients with resting mPAP <25 mmHg and pulmonary arterial wedge pressure ≤15 mmHg (n = 312) were stratified by mPAP <13, 13–16, 17–20, and 21–24 mmHg. Those with ePH (n = 35) were compared with resting precapillary pulmonary hypertension (rPH; n = 16) and to those with normal hemodynamics (non-PH; n = 224). ePH prevalence was 6%, 8%, and 27% for resting mPAP 13–16, 17–20, and 21–24 mmHg, respectively. Within each of these resting mPAP epochs, ePH negatively impacted exercise capacity compared with non-PH (peak oxygen uptake 70 ± 16% versus 92 ± 19% predicted, P < 0.01; 72 ± 13% versus 86 ± 17% predicted, P < 0.05; and 64 ± 15% versus 82 ± 19% predicted, P < 0.001, respectively). Overall, ePH and rPH had similar functional limitation (peak oxygen uptake 67 ± 15% versus 72 ± 13% predicted, P > 0.05) and similar underlying mechanisms of exercise intolerance compared with non-PH (peak oxygen delivery 1868 ± 599 mL/min versus 1756 ± 720 mL/min versus 2482 ± 875 mL/min, respectively; P < 0.05), associated with chronotropic incompetence, increased right ventricular afterload and signs of right ventricular/pulmonary vascular uncoupling. In conclusion, ePH is most frequently found in borderline mPAP, reducing exercise capacity in a manner similar to rPH. When borderline mPAP is identified at RHC, evaluation of the pulmonary circulation under the stress of exercise is warranted.

Keywords
pulmonary hypertension, exercise, oxygen uptake, oxygen delivery, pathophysiology

Date received: 10 February 2017; accepted: 19 April 2017

Pulmonary Circulation 2017; 7(3) 654–665
DOI: 10.1177/2045893217709025

Introduction
Pulmonary hypertension (PH) is currently defined by resting mean pulmonary arterial pressure (mPAP) ≥25 mmHg during a supine right heart catheterization (RHC).1 However, the normal resting mPAP value is known to be of 14 ± 3 mmHg and the upper limit of normal is approximately 20 mmHg.2 Consequently, a substantial number of
patients have abnormal resting mPAP values, though within
the non-diagnostic PH range.

There is growing evidence that borderline mPAP (21–24 mmHg) is associated with worse long-term outcomes. Recently, Maron et al. showed in a large heterogeneous population that resting mPAP 19–24 mmHg is associated with increased risk for hospitalization and mortality.3 Similarly, Kovacs et al. reported resting mPAP 21–24 mmHg to be associated with decreased exercise capacity and decreased survival.4 Furthermore, in patients with known risk factors for pulmonary vascular disease such as systemic sclerosis, several studies have demonstrated that borderline mPAP might be a unique clinical phenotype with associated worse prognosis.5–7

Similar to resting borderline mPAP, recent evidence suggests pre-capillary PH diagnosed during exercise (ePH) is a clinically relevant condition that is associated with symptoms, impacts exercise capacity and outcomes, and may progress to resting PH and might reflect an early (and likely more treatable) stage of established PH.8–15 Additionally, recent work from Lau et al. suggests ePH occurrence is high in borderline resting mPAP,16 pointing to the possible close association between these two conditions. However, the pathophysiologic link between borderline mPAP and ePH and the resultant functional impact of ePH in borderline mPAP remains incompletely characterized.

In the current study, we sought to evaluate the prevalence and functional implications of ePH across a spectrum of resting mPAP currently considered to be normal, including borderline mPAP, and to contrast ePH pathophysiological implications to those of resting precapillary pulmonary hypertension (rPH). We hypothesized ePH occurrence increases as a function of higher resting mPAP values, impacting exercise capacity in a manner similar to rPH.

**Methods**

We analyzed retrospectively 723 consecutive patients referred to the Brigham and Women’s Hospital Dyspnea Center over a 5.5-year period (from January 2012 until June 2016) with suspected PH who underwent resting supine RHC followed by an upright symptom-limited invasive cardiopulmonary exercise testing (iCPET) as part of their clinically indicated evaluation for unexplained exertional intolerance.17 The study protocol was approved by the Partners Human Research Committee (2011P000272).

According to resting supine RHC, patients were classified in two groups: those with mPAP < 25 mmHg and pulmonary arterial wedge pressure (PAWP) ≤15 mmHg; and those with mPAP ≥ 25 mmHg and/or PAWP > 15 mmHg (Fig. 1).

For the primary analysis, and in order to evaluate the prevalence and functional implications of ePH as a function of increasing resting mPAP at RHC, patients with mPAP < 25 mmHg and PAWP ≤ 15 mmHg were divided in four subgroups according to regular increasing resting mPAP intervals (<13 mmHg, 13–16 mmHg, 17–20 mmHg,
and 21–24 mmHg) (Fig. 1a). For the secondary analysis, and to evaluate ePH pathophysiological implications in relation to patients with resting established disease, ePH iCPET results were contrasted to those with rPH and those with normal resting/exercise pulmonary hemodynamics (non-PH) (Fig. 1b).

Exclusion criteria included: (1) anemia defined by hemoglobin concentration < 10 g.dL\(^{-1}\); (2) left heart disease (LHD) defined by moderate/severe mitral and/or aortic valvular disease or left ventricular ejection fraction < 0.5 at resting echocardiography, or postcapillary PH identified by mPAP ≥ 25 mmHg and PAWP > 15 mmHg at resting RHC or PAWP ≤ 15 mmHg at rest but abnormally elevated during exercise associated with a normal peak pulmonary vascular resistance (PVR) for the patient’s age (i.e. peak PAWP > 19 mmHg and peak PVR ≤ 1.35 WU for patients aged ≤ 50 years or PAWP > 17 mmHg and peak PVR ≤ 2.10 WU for patients aged > 50 years); (3) pulmonary mechanical limitation to exercise defined by ventilatory reserve at the anaerobic threshold ≥ 0.70; (4) submaximal cardiopulmonary exercise testing defined by peak respiratory exchange ratio (RER) < 1.05 and peak heart rate < 85% predicted and peak mixed-venous partial pressure of oxygen < 27 mmHg; and (5) incomplete exercise hemodynamics.

Baseline demographics, anthropometrics, co-morbidities, and contemporary pulmonary function testing and resting echocardiography were reviewed. A relevant lung disease was defined by the forced expiratory volume in the first second divided by forced vital capacity (FEV\(_1\)/FVC) < 70% predicted associated with FEV\(_1\) < 60% predicted, or a radiologic diagnosis of lung fibrosis associated with a FVC < 70% predicted.

**Pulmonary hypertension definitions**

ePH was defined by age-specific exercise pulmonary hemodynamic criteria for maximum upright exercise as follows: (1) peak mPAP > 30 mmHg and peak PVR > 1.34 WU for patients aged ≤ 50 years; or (2) peak mPAP > 33 mmHg and peak PVR > 2.10 WU for patients aged > 50 years. rPH was defined by resting supine RHC as mPAP ≥ 25 mmHg and PAWP ≤ 15 mmHg and PVR > 3 WU.22

**Hemodynamic measurements**

Our RHC and iCPET methods have been described in previous studies\(^{14,17,18}\) and is its technical aspects have been reported in detail elsewhere.\(^ {23}\) Briefly, RHC was performed in the supine position with a pulmonary arterial catheter (Edwards Lifesciences, Irvine, CA, USA) inserted percutaneously via the internal jugular vein and a concurrent catheter placed via the radial artery following a negative Allen’s test. Cardiac output (CO) at resting RHC was calculated using Fick’s method and an estimated oxygen consumption (VO\(_2\)).

With patients breathing room air, a symptom-limited incremental CPET was next performed using an upright cycle ergometer and a breath-by-breath metabolic cart (ULTIMA CPX; Medical Graphics Corporation, St Paul, MN, USA). Pulmonary and systemic hemodynamics were continuously and simultaneously monitored during exercise (Xper Cardio Physiomonitoring System; Philips, Melbourne, FL, USA). Pulmonary pressures were recorded at the end of a passive exhalation; when respirophasic changes persisted, an electronic average over three respiratory cycles was used. Arterial and mixed venous blood gases and pH were collected during each minute of exercise, and arterial-mixed venous oxygen content difference (Ca–vO\(_2\)) was calculated. By the Fick principle and using a simultaneously measured VO\(_2\), minute per minute CO was then obtained during exercise. Oxygen delivery (DO\(_2\)) was calculated multiplying CO by the arterial oxygen content (CaO\(_2\)).

Total pulmonary vascular resistance (TPR) and PVR were calculated by mPAP/CO and mPAP–PAWP/CO, respectively, and expressed as Wood units (WU). Pulmonary vascular compliance (PVC) was calculated by: stroke volume/systolic-diastolic PAP and expressed as mL/mmHg. Right ventricular stroke work index (RWSI) was calculated by: (1.25 mPAP–right atrial pressure × stroke volume index × 0.0136)\(^{25,27}\) and expressed as g/m/m\(^2\).

**Statistical analysis**

Unless otherwise stated, values are presented as mean and standard deviation or median and interquartile range. Group comparisons were performed using Chi-squared, Fisher’s exact tests, t-test, or Mann–Whitney U-test as appropriate. One-way ANOVA with Tukey’s post hoc analysis was used when comparing more than two groups. Receiver operating characteristic (ROC) curve analyses were derived for resting pulmonary hemodynamics while accounting for the presence or absence of ePH. P < 0.05 was considered significant. The statistical analyses were performed using SPSS software, version 19 (IBM Company, Armonk, NY, USA).

**Results**

Of the 723 iCPET reports analyzed, 271 (37%) had resting supine mPAP ≥ 25 mmHg and/or PAWP > 15 mmHg and 452 (63%) had mPAP < 25 mmHg and PAWP ≤ 15 mmHg at RHC (Fig. 1). For the primary analysis (Fig. 1a), 140 patients with mPAP < 25 mmHg and PAWP ≤ 15 mmHg were excluded due to anemia, echocardiographic abnormalities, pulmonary mechanical limitation to exercise, submaximum exercise test, and/or incomplete data. For the secondary analysis (Fig. 1b), 255 patients with mPAP ≥ 25 mmHg and/or PAWP > 15 mmHg were excluded based on RHC (elevated PAWP or elevated mPAP with normal PVR) or iCPET data (rPH with anemia, pulmonary limit, submaximum exercise test, and/or incomplete exercise hemodynamics), and 53
patients with mPAP < 25 mmHg and PAWP ≤ 15 mmHg were excluded due to LHD diagnosed only during exercise.

**Resting mPAP < 13 versus 13–16 versus 17–20 versus 21–24 mmHg**

In total, 312 patients with mPAP < 25 mmHg and PAWP ≤ 15 mmHg were analyzed. Twenty-seven patients had mPAP < 13 mmHg, 96 mPAP 13–16 mmHg, 115 mPAP 17–20 mmHg, and 74 mPAP 21–24 mmHg (Fig. 1a). Their resting mPAP distribution is presented in the online supplementary material (Fig. S1).

Age, body mass index (BMI), and the presence of comorbidities increased as a function of higher resting mPAP values and a mPAP within the borderline range (21–24 mmHg) was significantly associated with older age and elevated BMI. At RHC, there was progressively higher PVR and TPR and lower PVC as a function of higher mPAPs. Their baseline characteristics and RHC data are summarized in Table 1.

During iCPET, higher resting mPAP values were associated with decreased exercise capacity, as measured by peak VO₂ (Table 2). Also, decreased peak CaO₂ and decreased peak DO₂ were observed in borderline mPAP. Exercise hemodynamics additionally revealed decreased peak CO and increased peak right atrial pressure, peak TPR, and peak PVR in patients with resting borderline mPAP (Table 2).

Based on the aforementioned exercise hemodynamic criteria, ePH occurred in 6% (6 out of 96) of patients with mPAP 13–16 mmHg, 8% (9 out of 115) of patients with mPAP 17–20 mmHg and 27% (20 out of 74) of those with mPAP 21–24 mmHg (Fig. 2).

**ePH versus rPH versus non-PH**

In total, 35 ePH, 16 rPH, and 224 non-PH patients were analyzed (Fig. 1b). Compared with non-PH, ePH had higher resting mPAP (20 ± 3 mmHg versus 17 ± 3 mmHg, P < 0.05) and PVR (2.1 ± 0.8 WU versus 1.3 ± 0.5 WU, P < 0.05) and lower PVC (4.3 ± 1.6 mL/mmHg versus 6.2 ± 2.1 mL/mmHg, P < 0.05) at RHC. rPH had resting mPAP of 36 ± 11 mmHg, PAWP 10 ± 3 mmHg, TPG 27 ± 10 mmHg, PVR 5.7 ± 2.8 WU at RHC. rPH and ePH tended to be older compared with non-PH (62 ± 11 versus 59 ± 16 versus 53 ± 16, P = 0.02, respectively) and had more co-morbidities such as systemic hypertension, connective tissue disease, diabetes mellitus, and history of pulmonary embolism. Detailed baseline characteristics and RHC data for rPH, ePH, and non-PH are presented in the online supplementary material (Table S1).

Patients with ePH had elevated mPAP/C0 slopes compared with non-PH across the different mPAP ranges (Fig. 3), and within each resting mPAP epoch, the development of ePH was associated with a significantly reduced peak VO₂ as a % predicted compared with non-PH (Fig. 4).

In the aggregate, ePH and rPH had similarly reduced exercise capacity compared with non-PH as shown by their reduced peak VO₂, which in turn was associated with decreased peak CaO₂, peak CO, and peak DO₂, and indices of decreased right ventricular function and increased right ventricular and pulmonary vascular load (Table 3). ePH and rPH also showed chronotropic incompetence at peak exercise (Table 3). In ePH, chronotropic incompetence occurred predominately in patients aged > 50 years (Table S2) and irrespective of the use of beta-adrenergic receptor blockers (Table S3).

rPH additionally had a reduced peak Ca-VO₂ (Table 3). Peak alveolar-arterial oxygen tension difference was elevated in rPH and ePH compared with non-PH (64 ± 14 mmHg versus 35 ± 20 mmHg versus 17 ± 16 mmHg, respectively; P < 0.05). Arterial oxygen saturation was reduced in rPH and ePH compared with non-PH (85 ± 6% versus 93 ± 4% versus 97 ± 5%, respectively; P < 0.05).

The analysis of minute per minute PVR versus PVC relationship during exercise (n=2129 individual data points obtained from the 224 non-PH patients, n=294 from the 35 ePH and n=115 from the 16 rPH) revealed that ePH pulmonary hemodynamic response to exercise was intermediate between non-PH and rPH (Fig. 5a). Additionally, by the logarithmic transformation of PVR and PVC (Fig. 5b), a progressive downward-leftward change of PVR versus PVC relation was observed for ePH compared with non-PH during exercise, reflecting the dynamic pulmonary vascular responses that led ePH to be an intermediate pulmonary hemodynamic stage between normality and established disease.

**RHC ePH predictors**

By ROC analysis, resting supine mPAP, PVR, and PVC provided prediction information about the presence or absence of ePH (AUC = 0.76, 95% CI = 0.68–0.85, P < 0.01; AUC = 0.78, 95% CI = 0.69–0.88, P < 0.01; and AUC = 0.76, 95% CI = 0.67–0.84, P < 0.01, respectively). Their optimal cutoff values to separate ePH from non-PH were 19 mmHg for resting mPAP, 1.6 WU for resting PVC, and 4.6 mL/mmHg for resting PVC. Of the ePH patients, 83% had a mPAP ≥ 19 mmHg and/or a PVR ≥ 1.6 WU at resting supine RHC.

**Discussion**

In the present study, we demonstrate that the prevalence of ePH increases as a function of higher resting mPAP values and is found in 27% of the patients with borderline mPAP (21–24 mmHg). When present, ePH substantially affects exercise capacity regardless of the resting mPAP range and the functional impact of ePH is similar than that observed in rPH. ePH and rPH have shared mechanisms of exercise intolerance, suggesting that ePH represents an early pathophysiological stage of rPH. The current findings indicate
Table 1. Baseline characteristics according to the resting mean pulmonary arterial pressure (mPAP) at right heart catheterization.

|                           | mPAP < 13 mmHg | mPAP 13–16 mmHg | mPAP 17–20 mmHg | mPAP 21–24 mmHg |
|---------------------------|----------------|-----------------|-----------------|----------------|
| Participants              | 27             | 96              | 115             | 74             |
| Age (years)               |                |                 |                 |                |
|                         | 49 ± 11         | 51 ± 16         | 56 ± 16         | 62 ± 13^a,b     |
| Women (n (%))             | 17 (63)         | 70 (73)         | 65 (67)         | 39 (53)        |
| BMI (kg/m²)               | 26.3 ± 5.8      | 26.6 ± 6.4      | 29.1 ± 6.5^a    | 30.1 ± 6.2^a    |
| Hemoglobin (g/dL)         | 14.3 ± 1.4      | 14.0 ± 1.5      | 14.2 ± 1.6      | 13.7 ± 1.5     |
| Co-morbidities (n (%))    |                |                 |                 |                |
| None                      | 17 (63)         | 48 (50)         | 41 (36)         | 19 (26)        |
| Hypertension              | 4 (15)          | 28 (29)         | 50 (43)         | 38 (51)        |
| Connective tissue disease | 2 (7)           | 6 (6)           | 11 (10)         | 12 (16)        |
| Diabetes mellitus         | 1 (4)           | 3 (3)           | 13 (11)         | 9 (12)         |
| Lung disease              | 0               | 2 (2)           | 5 (4)           | 6 (8)          |
| Smokers                   | 0               | 3 (3)           | 4 (3)           | 1 (1)          |
| History of pulmonary embolism | 0           | 6 (6)           | 8 (7)           | 7 (9)          |
| Medications (n (%))       |                |                 |                 |                |
| Diuretics                 | 4 (15)          | 10 (10)         | 23 (20)         | 16 (22)        |
| ACE inhibitor or ARB      | 6 (22)          | 26 (27)         | 44 (38)         | 29 (39)        |
| Beta-adrenergic receptor blocker | 2 (7)         | 11 (11)         | 26 (23)         | 19 (26)        |
| Calcium channel blocker   | 2 (7)           | 8 (8)           | 13 (11)         | 12 (16)        |
| Pulmonary function testing |                |                 |                 |                |
| FEV₁ (% predicted)        | 97 ± 13         | 94 ± 16         | 87 ± 19^a,b     | 82 ± 18^a,b     |
| FVC (% predicted)         | 98 ± 13         | 94 ± 17         | 87 ± 19^a,b     | 83 ± 17^a,b     |
| FEV₁/FVC (% predicted)    | 99 ± 5          | 100 ± 8         | 99 ± 10         | 98 ± 12        |
| Echocardiography          |                |                 |                 |                |
| LA AP diameter (mm)       | 35 ± 4          | 35 ± 5          | 36 ± 5          | 38 ± 6^a       |
| LVEF (%)                  | 63 ± 6          | 62 ± 4          | 62 ± 4          | 62 ± 5         |
| TRV (m/s)                 | 2.2 ± 0.3       | 2.3 ± 0.3       | 2.4 ± 0.4^*     | 2.5 ± 0.3^a     |
| Estimated sPAP (mmHg)     | 22 ± 9          | 23 ± 5          | 27 ± 7^*        | 28 ± 7^a       |
| Right heart catheterization |                |                 |                 |                |
| RA (mmHg)                 | 4 ± 2           | 5 ± 2           | 7 ± 2^a         | 7 ± 3^a,b       |
| mPAP (mmHg)               | 11 ± 1          | 15 ± 1^a        | 18 ± 1^a,b      | 22 ± 1^a,b,c    |
| PAWP (mmHg)               | 6 ± 2           | 9 ± 2^a         | 11 ± 2^a,b      | 13 ± 3^a,b,c    |
| TPG (mmHg)                | 5 ± 2           | 6 ± 2           | 7 ± 3^a,b       | 9 ± 3^a,b,c     |
| CO (L/min)                | 4.8 ± 1.0       | 5.4 ± 1.1       | 5.4 ± 1.1       | 5.5 ± 1.3      |
| CI (L/min/m²)             | 2.7 ± 0.6       | 2.9 ± 0.6       | 2.8 ± 0.5       | 2.8 ± 0.6      |
| TPR (WU)                  | 2.5 ± 0.7       | 2.9 ± 0.6       | 3.5 ± 0.7^a,b   | 4.3 ± 1.2^a,b   |
| PVR (WU)                  | 1.0 ± 0.4       | 1.1 ± 0.4       | 1.4 ± 0.6^a,b   | 1.8 ± 0.7^a     |
| PVC (mL/mmHg)             | 7.3 ± 2.4       | 6.5 ± 2.2       | 5.8 ± 1.9^*     | 4.7 ± 1.9^a     |

Data are presented as n, n (%), or mean ± standard deviation.

^aP < 0.05 compared with mPAP < 13 mmHg.

^bP < 0.05 compared with mPAP 13–16 mmHg.

^cP < 0.05 compared with mPAP 17–20 mmHg.

BMI, body mass index; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor antagonist; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity; LA AP, left atrium anteroposterior; LVEF, left ventricular ejection fraction; TRV, tricuspid regurgitant jet velocity; sPAP, systolic pulmonary arterial pressure; RA, right atrial pressure; mPAP, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; TPG, transpulmonary gradient; CO, cardiac output; CI, cardiac index; TPR, total pulmonary vascular resistance; PVR, pulmonary vascular resistance; PVC, pulmonary vascular compliance.
Table 2. Upright invasive cardiopulmonary exercise data according to the resting mean pulmonary arterial pressure (mPAP) at right heart catheterization.

| Participants | mPAP < 13 mmHg | mPAP 13–16 mmHg | mPAP 17–20 mmHg | mPAP 21–24 mmHg |
|--------------|----------------|-----------------|-----------------|-----------------|
| Maximum work rate (W) | 137 ± 50 | 134 ± 54 | 123 ± 49 | 102 ± 42<sup>‡‡</sup> |
| Peak VO<sub>2</sub> (% predicted) | 90 ± 21 | 91 ± 22 | 83 ± 18<sup>‡</sup> | 75 ± 19<sup>‡‡</sup> |
| Peak VO<sub>2</sub> (mL/kg/min) | 23.6 ± 8.1 | 22.5 ± 8.5 | 19.2 ± 6.4<sup>‡</sup> | 15.7 ± 5.3<sup>‡‡</sup> |
| VO<sub>2</sub> at AT (% VO<sub>2</sub>MAX predicted) | 49 ± 12 | 51 ± 17 | 45 ± 10† | 43 ± 13† |
| Peak heart rate (bpm) | 151 ± 18 | 151 ± 25 | 142 ± 26<sup>†</sup> | 129 ± 27<sup>‡‡</sup> |
| Peak heart rate (% predicted) | 88 ± 11 | 89 ± 11 | 86 ± 12 | 80 ± 14<sup>‡‡</sup> |
| Peak RAP (mmHg) | 1.19 ± 0.12 | 1.14 ± 0.12 | 1.14 ± 0.13 | 1.12 ± 0.11 |
| Peak VE/MVV | 64 ± 16 | 60 ± 16 | 66 ± 21 | 64 ± 17 |
| VE/VCO<sub>2</sub> slope | 32 ± 8 | 31 ± 6 | 32 ± 8 | 36 ± 10<sup>‡</sup> |
| Peak P<sub>A-a</sub>O<sub>2</sub> (mmHg) | 11 ± 11 | 17 ± 12 | 18 ± 19 | 28 ± 19<sup>‡‡</sup> |
| Peak SaO<sub>2</sub> (%) | 98 ± 1 | 97 ± 2 | 96 ± 7 | 95 ± 4 |
| Peak CaO<sub>2</sub> (mL/dL) | 19.5 ± 1.9 | 19.1 ± 2.4 | 19.5 ± 2.3 | 18.3 ± 2.2† |
| Peak Ca-vO<sub>2</sub> (mL/dL) | 13.2 ± 1.8 | 12.6 ± 2.0 | 12.7 ± 2.0 | 12.2 ± 2.0 |
| Peak DO<sub>2</sub> (mL/min) | 2535 ± 884 | 2541 ± 930 | 2490 ± 871 | 2012 ± 707<sup>‡‡</sup> |
| Peak DO<sub>2</sub> (mL/kg/min) | 34.7 ± 11.4 | 34.2 ± 12.4 | 29.8 ± 9.8<sup>‡</sup> | 23.5 ± 9.8<sup>‡‡</sup> |

Exercise hemodynamics

| | Peak RAP (mmHg) | Peak mPAP (mmHg) | Peak PAWP (mmHg) | Peak TPG (mmHg) | Peak CO (L/min) | Peak CI (L/min/m²) | Peak SV (mL) | Peak SVI (mL/m²) | Peak TPR (WU) | Peak PVR (WU) | Peak PVC (mL/mmHg) | Peak RVSWI (g/m²) |
|---|----------------|-----------------|-----------------|----------------|-----------------|-----------------|-------------|---------------|---------------|--------------|------------------|-------------------|
| | 5 ± 4 | 23 ± 6 | 10 ± 4 | 13 ± 4 | 128 ± 3.7 | 7.0 ± 1.8 | 85 ± 23 | 47 ± 12 | 1.9 ± 0.5 | 1.1 ± 0.4 | 3.6 ± 1.4 | 15.4 ± 6.6 |
| | 6 ± 4 | 26 ± 7 | 12 ± 5 | 14 ± 5 | 131 ± 3.9 | 7.0 ± 1.9 | 88 ± 25 | 47 ± 11 | 2.2 ± 0.8 | 1.2 ± 0.6 | 3.6 ± 1.6 | 17.4 ± 6.7 |
| | 7 ± 5 | 29 ± 8<sup>‡</sup> | 14 ± 6<sup>*</sup> | 16 ± 6 | 127.3 ± 3.9 | 6.4 ± 1.7<sup>‡</sup> | 90 ± 24 | 46 ± 10 | 2.5 ± 0.9<sup>*</sup> | 1.3 ± 0.6 | 3.3 ± 1.4 | 18.6 ± 6.8 |
| | 9 ± 5<sup>‡‡</sup> | 34 ± 8<sup>‡‡</sup> | 16 ± 6<sup>*</sup> | 19 ± 7<sup>‡</sup> | 10.9 ± 3.3<sup>‡‡</sup> | 5.5 ± 1.5<sup>‡‡</sup> | 86 ± 20 | 43 ± 7<sup>*</sup> | 3.5 ± 1.5<sup>‡‡</sup> | 1.8 ± 0.9<sup>‡‡</sup> | 3.1 ± 1.2 | 19.8 ± 6.6<sup>‡</sup> |

Data are presented as n or mean ± standard deviation.
<sup>‡</sup>P < 0.05 compared with mPAP < 13 mmHg.
<sup>‡</sup>P < 0.05 compared with mPAP 13–16 mmHg.
<sup>‡‡</sup>P < 0.05 compared with mPAP 17–20 mmHg.

VO<sub>2</sub>, oxygen uptake; VO<sub>2</sub>MAX, maximal oxygen uptake; AT, anaerobic threshold; RER, respiratory exchange ratio; VE/MVV, ventilatory reserve; VE/VCO<sub>2</sub>, ventilatory equivalent for carbon dioxide; P<sub>A-a</sub>O<sub>2</sub>, alveolar–arterial oxygen tension difference; SaO<sub>2</sub>, arterial oxygen saturation; CaO<sub>2</sub>, arterial oxygen content; Ca-vO<sub>2</sub>, arterial–mixed venous oxygen content difference; DO<sub>2</sub>, oxygen delivery; RAP, right atrial pressure; mPAP, mean pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; TPG, transpulmonary gradient; CO, cardiac output; CI, cardiac index; SV, stroke volume; SVI, stroke volume index; TPR, total pulmonary vascular resistance; PVR, pulmonary vascular resistance; PVC, pulmonary vascular compliance; RVSWI, right ventricular stroke work index.

that the identification of borderline mPAP at RHC should encourage the evaluation of the pulmonary circulation under the stress of exercise to uncover clinically relevant early pulmonary vascular disease.

**Prevalence of ePH in borderline mPAP**

Our results reveal that ePH prevalence is elevated in borderline mPAP (Fig. 2), but lower than that previously reported. Lau et al. recently described a 65% prevalence of pre-capillary PH during exercise for mPAP 21–24 mmHg; however, the aforementioned study evaluated patients from a PH Referral Center with an elevated prevalence of PH risk factors. Conversely, the present study evaluated patients from a Dyspnea Center, which encompass a heterogeneous patient population with unexplained exertional intolerance. To our knowledge, the current study is the largest to date to evaluate directly measured invasive exercise hemodynamics as a function of increasing resting mPAP values in a general population undergoing
dyspnea investigation and therefore, might more accurately reflect ePH real-life prevalence across different resting mPAP ranges. Despite differences in ePH prevalence, our findings and those of Lau et al. agree that increasing resting mPAP values are associated with increased ePH occurrence, reinforcing the notion that borderline mPAP should be considered a population at risk for ePH development.

We additionally observed that increasing resting mPAP values were associated with increasing age, BMI, and co-morbidities rate (Table 1), which were followed by progressively abnormal exercise pulmonary hemodynamics (Table 2). These findings are in accord with those of others and likely reflect the association between the presence of co-morbidities and PH risk factors and the development of abnormal pulmonary vascular responses during exercise.

**Functional impact of ePH in borderline mPAP**

A key finding of the current study is that regardless of the resting mPAP range, the development of ePH is associated with a reduced exercise capacity (Fig. 4). This finding highlights the additive value of exercise hemodynamics to detect early disease. Additionally, using simultaneously measured
maximum incremental VO\textsubscript{2} (and its indirect determinants) and invasive pulmonary hemodynamics, we demonstrate for the first time that ePH and rPH have similar mechanisms underlying exercise intolerance, specifically, impaired DO\textsubscript{2} and indices of increased right ventricular and pulmonary vascular load and chronotropic incompetence (Table 3).

The decreased peak DO\textsubscript{2} was associated with concurrent reduction of peak CaO\textsubscript{2} and peak CO for both ePH and rPH. While the reduced peak CaO\textsubscript{2} reflects the known impact of pulmonary vascular disease on the oxygen diffusion through the vascular bed,\textsuperscript{28} the decreased peak CO is likely a result of increased right ventricular afterload (seen by abnormal peak PVR and peak PVC) and right ventricular/pulmonary vascular uncoupling (suggested by the elevated peak right atrial pressure and RVSWI) in both ePH and rPH (Table 3).

Right ventricular maladaptation to increased pulmonary vascular load is a known phenomenon in pulmonary arterial hypertension.\textsuperscript{29-31} In the current study, we found signs of dynamic (only during exercise) right ventricular/pulmonary vascular uncoupling in ePH associated with elevated right heart afterload and right ventricular work, in a similar manner to that found for rPH (Table 3). Ventriculoarterial uncoupling is associated with worse prognosis in established PH;\textsuperscript{32} therefore, we speculate that this very similar pathophysiology we have observed in ePH may account for their adverse outcomes recently described by others.\textsuperscript{15} However, the present study was cross-sectional by design and future longitudinal studies are needed to address the underlying link between ePH and long-term outcomes.

ePH and rPH also had chronotropic incompetence that contributed to their reduced exercise capacity (Table 3). In ePH, this occurred largely in participants aged \textgtr 50 years (Table S2) and was not strictly related to medication use (Table S3). In resting established PH, chronotropic incompetence has been associated with right heart failure and autonomic imbalance.\textsuperscript{33-36} Additionally, recent data suggest that in post-pulmonary endarterectomy patients with ePH, chronotropic incompetence might also occur.\textsuperscript{37} In our study, the chronotropic incompetence observed in older ePH patients was accompanied by indices of increased right ventricular work to an increased pulmonary vascular load (Table S3), suggesting therefore association with disease severity (i.e. autonomic imbalance due to right ventricular dysfunction\textsuperscript{35,36}), rPH also had a reduced peripheral oxygen extraction, as seen by the blunted Ca-vO\textsubscript{2} difference at peak exercise (Table 3), which likely reflect an associated skeletal muscle dysfunction\textsuperscript{38,39} and the multifactorial causes of exercise limitation in rPH.\textsuperscript{40,41}

Taken together, the current findings provide important insight into the mechanisms of exercise intolerance in early pulmonary vascular disease. The results confirm previous non-invasive exercise findings in resting established PH\textsuperscript{41} and additionally suggest that oxygen delivery is impaired in the early stages of pulmonary vascular disease (i.e. ePH).

Recently, Kovacs et al. demonstrated that patients with borderline mPAP have decreased exercise capacity,\textsuperscript{4} a finding confirmed by the current study (Table 2). However, our data indicate that patients with borderline mPAP have a heterogeneous pulmonary vascular response to exercise, including patients with and without ePH, and that only
those who develop ePH will suffer a functional limitation (Fig. 4). Therefore, our data suggest that ePH rather than borderline mPAP per se more precisely reflects an early stage of pulmonary vascular dysfunction until maximum incremental cycling exercise protocol to the one used in the current study. Considering ePH (rather than borderline resting mPAP) as an early stage of pulmonary vascular disease might be of major clinical relevance, potentially allowing early and more effective therapeutic interventions that could impact PH natural history.

Predictive value of RHC for ePH

In addition to resting mPAP, other RHC measurements such as PVR and PVC also provided predictive information regarding ePH occurrence. This finding is of major clinical relevance and may provide additional framework for the identification of subgroups at a higher risk for ePH development and should stimulate further investigation. However, given the methodological limitations of the current study, the substantial variability of pulmonary vascular dysfunction across different resting RHC patterns, exercise hemodynamics should remain indispensable for the detection of early stages of pulmonary vascular dysfunction until more robust evidence is generated.

Limitations

The study sample was derived from a tertiary dyspnea center and therefore the generalization of our findings should be done with caution. Non-PH patients were symptomatic and our sample reflect a heterogeneous population undergoing investigation for unexplained exertional intolerance. rPH and ePH patients also reflect a heterogeneous population that included patients with suspected PH of different causes. However, a subanalysis according to cardiovascular co-morbidities and PH risk factors revealed similar findings compared to those of the entire population (Tables S4 and S5), indicating that the mechanisms underlying their impaired exercise capacity are similar and that the hemodynamic profile had a central role influencing exercise intolerance. Our rPH population was relatively small in sample size due to the infrequency that participants with established resting disease undergo iCPET in our center and was older compared to non-PH and ePH, what might have influenced our rPH exercise hemodynamic findings. Additionally, due to the nature of the iCPET clinical referrals (i.e. investigation of unexplained exercise intolerance), rPH was mild in severity, which likely mitigated the changes during exercise that would have been seen with more severe disease. However, rPH were selected based on RHC criteria supported by current guidelines and represent a well-established spectrum of pulmonary vascular disease.

For the ePH definition, we used age-related mPAP and PVR thresholds, derived from the study of physiologically normal participants that underwent an identical upright incremental cycling exercise protocol to the one used in the current study. This age-specific ePH criteria addresses one of the major concerns that led to the exclusion of the ePH definition from the PH guidelines in 2008 (i.e. the uncertainty of the upper limits of normal for pulmonary hemodynamics in participants aged >50 years) and
therefore likely decreases the number of false positive/negative diagnoses of ePH as a function of normal aging. The use of exercise hemodynamic thresholds determined by age is supported by additional recent evidence that pulmonary hemodynamics vary according to age in well-defined normal participants. Nonetheless, there was 92.66% concordance between the ePH definition used in the current study and the alternative proposed ePH criteria that uses a peak mPAP > 30 mmHg and peak TPR > 3 WU regardless of age.

A subanalysis comparing the different ePH criteria is presented in the online supplementary material (Fig. S2 and Tables S6–S8). Considering peak VO₂ as a marker of the presence/absence of disease, the age-specific ePH criteria demonstrated better sensitivity for participants aged ≤50 years and better specificity for participants aged >50 years (Table S4). These additional findings reinforce the potential role of age-specific exercise hemodynamic thresholds to identify clinically relevant abnormal pulmonary hemodynamic responses to exercise. However, our ePH criteria has not been externally validated and therefore further studies are necessary to confirm our findings.

Resting RHC CO was calculated using the Fick principle and an estimated VO₂; therefore, resting supine CO-derived variables should be interpreted with caution. We did not use high-fidelity catheters to acquired pulmonary hemodynamic measurements, and more specifically pulmonary pulse pressure, during exercise; therefore, PVC findings should be carefully interpreted. During iCPET, pulmonary pressures were either measured through a passive exhalation, or using an electronic average over the respiratory cycle. The use of different techniques to measure pulmonary pressures might be considered a confounding factor, but it has been our observation that the pulmonary vascular pressures obtained during the passive exhalation technique do not differ from an average through the respiratory cycle in patients able to perform both. Finally, we did not directly measure right ventricular contractile reserve during exercise and did not evaluate the long-term prognostic implications of ePH. Therefore, future studies are needed to address these issues.

**Conclusions**

The prevalence of ePH increases as a function of higher resting mPAP values currently considered in the normal range and is most frequently found in borderline mPAP. The development of ePH substantively affects exercise capacity regardless of the resting mPAP, and ePH and rPH share an underlying impaired oxygen delivery, increased right heart afterload, signs of right ventricular/pulmonary vascular uncoupling, and chronotropic incompetence that reduce exercise capacity. The current findings indicate that in the presence of borderline mPAP at RHC, evaluation of the pulmonary circulation under the stress of exercise is warranted to uncover physiologically and clinically relevant early pulmonary vascular disease.
Conflict of interest
The authors declare that there is no conflict of interest.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References
1. Galie N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *Eur Respir J* 2015; 46: 903–975.
2. Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. *Eur Respir J* 2009; 34: 888–894.
3. Maron BA, Hess E, Maddox TM, et al. Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the Veterans Affairs clinical assessment, reporting, and tracking program. *Circulation* 2016; 133: 1240–1248.
4. Kovacs G, Avian A, Tscherner M, et al. Characterization of patients with borderline pulmonary arterial pressure. *Chest* 2014; 146: 1486–1493.
5. Kovacs G, Maier R, Aberer E, et al. Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma. *Am J Respir Crit Care Med* 2009; 180: 881–886.
6. Visovatti SH, Distler O, Coghlan JG, et al. Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. *Arthritis Res Ther* 2014; 16: 493.
7. Heresi GA, Minai OA, Tonelli AR, et al. Clinical characterization and survival of patients with borderline elevation in pulmonary artery pressure. *Pulm Circ* 2013; 3: 916–925.
8. Tolle JJ, Waxman AB, Van Horn TL, et al. Exercise-induced pulmonary arterial hypertension. *Circulation* 2008; 118: 2183–2189.
9. Steen V, Chou M, Shanmugam V, et al. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. *Chest* 2008; 134: 146–151.
10. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. *Am J Respir Crit Care Med* 2009; 179: 151–157.
11. Fowler RM, Maiorana AJ, Jenkins SC, et al. Implications of exercise-induced pulmonary arterial hypertension. *Med Sci Sports Exerc* 2011; 43: 983–989.
12. Saggar R, Khanna D, Furst DE, et al. Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities. *Arthritis Rheum* 2010; 62: 3741–3750.
13. Herve P, Lau EM, Sitbon O, et al. Criteria for diagnosis of exercise pulmonary hypertension. *Eur Respir J* 2015; 46: 728–737.
14. Oliveira RKF, Waxman AB, Agarwal M, et al. Pulmonary haemodynamics during recovery from maximum incremental cycling exercise. *Eur Respir J* 2016; 48: 158–167.
15. Stamm A, Saxer S, Lichtblau M, et al. Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. *Eur Respir J* 2016; 48: 1658–1667.
16. Lau EMT, Godinas L, Sitbon O, et al. Resting pulmonary artery pressure of 21–24 mmHg predicts abnormal exercise haemodynamics. *Eur Respir J* 2016; 47: 1436–1444.
17. Maron BA, Cockrill BA, Waxman AB, et al. The invasive cardiopulmonary exercise test. *Circulation* 2013; 127: 1157–1164.
18. Oliveira RKF, Agarwal M, Tracy JA, et al. Age-related upper limits of normal for maximum upright exercise pulmonary haemodynamics. *Eur Respir J* 2016; 47: 1179–1188.
19. Medoff BD, Oelberg DA, Kanarek DJ, et al. Breathing reserve at the lactate threshold to differentiate a pulmonary mechanical from cardiovascular limit to exercise. *Chest* 1998; 113: 913–918.
20. Edwards RH, Denison DM, Jones G, et al. Changes in mixed venous gas tensions at start of exercise in man. *J Appl Physiol* 1972; 32: 165–169.
21. Seeger W, Adir Y, Barberá JA, et al. Pulmonary hypertension in chronic lung diseases. *J Am Coll Cardiol* 2013; 62: D109–116.
22. Hoeppe MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. *J Am Coll Cardiol* 2013; 62: D42–50.
23. Berry NC, Manyoo A, Oldham WM, et al. Protocol for exercise hemodynamic assessment: performing an invasive cardiopulmonary exercise test in clinical practice. *Pulm Circ* 2015; 5: 610–618.
24. Boerrigter BG, Waxman AB, Westerhof N, et al. Measuring central pulmonary pressures during exercise in COPD: how to cope with respiratory effects. *Eur Respir J* 2014; 43: 1316–1325.
25. Her C. Right ventricular stroke-work. An index of distribution of pulmonary perfusion in acute respiratory failure. *Chest* 1983; 84: 719–724.
26. Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2010; 182: 252–260.
27. Chemla D, Castelain V, Zhu K, et al. Estimating right ventricular stroke work and the pulsatile work fraction in pulmonary arterial hypertension. *Chest* 2013; 143: 1343–1350.
28. Sun X-G, Hansen JE, Oudiz RJ, et al. Pulmonary function in primary pulmonary hypertension. *J Am Coll Cardiol* 2003; 41: 1028–1035.
29. Spruijt OA, de Man FS, Groepenhoff H, et al. The effects of exercise on right ventricular contractility and right ventricular arterial coupling in pulmonary hypertension. *Am J Respir Crit Care Med* 2015; 191: 1050–1057.
30. Vonk Noordegraaf A, Westerhof BE and Westerhof N. The relationship between the right ventricle and its load in pulmonary hypertension. *J Am Coll Cardiol* 2017; 69: 236–243.
31. Hsu S, Houston BA, Tampakakis E, et al. Right ventricular functional reserve in pulmonary arterial hypertension. *Circulation* 2016; 133: 2413–2422.
32. Vonk-Noordegraaf A, Haddad F, Chin KM, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. *J Am Coll Cardiol* 2013; 62: D22–33.
33. Velez-Roa S, Ciarka A, Najem B, et al. Increased sympathetic nerve activity in pulmonary artery hypertension. *Circulation* 2004; 110: 1308–1312.
34. Naeije R and van de Borne P. Clinical relevance of autonomic nervous system disturbances in pulmonary arterial hypertension. *Eur Respir J* 2009; 34: 792–794.

35. Bristow MR, Minobe W, Rasmussen R, et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. *J Clin Invest* 1992; 89: 803–815.

36. Wensel R, Jilek C, Dörr M, et al. Impaired cardiac autonomic control relates to disease severity in pulmonary hypertension. *Eur Respir J* 2009; 34: 895–901.

37. Claessen G, La Gerche A, Dymarkowski S, et al. Pulmonary vascular and right ventricular reserve in patients with normalized resting hemodynamics after pulmonary endarterectomy. *J Am Heart Assoc* 2015; 4: e001602.

38. Tolle J, Waxman A and Systrom D. Impaired systemic oxygen extraction at maximum exercise in pulmonary hypertension. *Med Sci Sports Exerc* 2008; 40: 3–8.

39. Potus F, Malenfant S, Graydon C, et al. Impaired angiogenesis and peripheral muscle microcirculation loss contribute to exercise intolerance in pulmonary arterial hypertension. *Am J Respir Crit Care Med* 2014; 190: 318–328.

40. Galie N, Manes A and Palazzini M. Exercise training in pulmonary hypertension: improving performance but waiting for outcome. *Eur Heart J* 2016; 37: 45–48.

41. Sun XG, Hansen JE, Oudiz RJ, et al. Exercise pathophysiology in patients with primary pulmonary hypertension. *Circulation* 2001; 104: 429–435.

42. Maron BA and Abman SH. Translational advances in the field of pulmonary hypertension. focusing on developmental origins and disease inception for the prevention of pulmonary hypertension. *Am J Respir Crit Care Med* 2017; 195: 292–301.

43. Wolsk E, Bakkestrom R, Thomsen JH, et al. The influence of age on hemodynamic parameters during rest and exercise in healthy individuals. *JACC Heart Fail* 2017; 5: 337–46.